DEPLOYDatabase

Robot model

Wandercraft Eve

Personal-use self-balancing walking exoskeleton from Wandercraft, the take-home counterpart to the clinic-based Atalante X.

Manufacturer
Wandercraft
Form factor
exoskeleton
Maturity
commercial
Lifecycle
active

The verified answer

As of Sep 2026, DEPLOY verifies Wandercraft Eve, a exoskeleton by Wandercraft (commercial). 3 sources back the record.

Overview

Personal-use self-balancing walking exoskeleton from Wandercraft, the take-home counterpart to the clinic-based Atalante X. Like Atalante it walks hands-free, without crutches, using AI-driven dynamic balance. The FDA cleared Eve in August 2026 for eligible adults with spinal cord injuries at any level, provided the user can operate the device's remote control, following a three-site clinical trial that met its functional and usability endpoints. Wandercraft set a US commercial launch for 17 September 2026.

Verified vs. claimed

Maturity stage
commercial(Commercially deployed with revenue-generating operations.)
Sources on file
View all sources →

No verified deployments on file. DEPLOY tracks independently-sourced deployment evidence separately from manufacturer capability claims.

Specs

Use

personal, prescribed take-home use

Control

AI-driven autonomous dynamic balance, hands-free, no crutches; user operates a remote control

Regulatory

FDA cleared August 2026, spinal cord injury at any level for eligible adults

Availability

US commercial launch announced for 17 September 2026

Not disclosed

price, mass and battery runtime are not stated by Wandercraft

Reimbursement

Medicare DMEPOS pathway for personal exoskeletons exists under billing code K1007

Data & sources

Web sources

3

3 sources backing this record.View all →

Pricing

No verified price is on record for Wandercraft Eve. Physical-AI systems are often sold through enterprise contracts or operated as a service rather than at a public list price.

Recent activity

Every change to this record is dated, sourced, and independently verified where marked.

Full change history →

Safety record

No incidents on record for Wandercraft Eve.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Sources (3)

  1. Wandercraft Receives FDA Clearance for Eve · https://www.wandercraft.eu/articles/wandercraft-receives-fda-clearance-for-eve-the-worlds-first-self-balancing-personal-exoskeleton-for-eligible-wheelchair-users-living-with-spinal-cord-injuries-at-any-level
  2. Wandercraft wins FDA clearance for self-balancing exoskeleton · https://www.massdevice.com/wandercraft-wins-fda-clearance-for-self-balancing-exoskeleton/
  3. FDA Clearance for Eve, Wandercraft's Personal Use Self-Balancing Walking Exoskeleton · https://exoskeletonreport.com/2026/08/fda-clearance-for-eve-wandercrafts-personal-use-self-balancing-walking-exoskeleton/

Common questions

What is Wandercraft Eve?
Personal-use self-balancing walking exoskeleton from Wandercraft, the take-home counterpart to the clinic-based Atalante X. Like Atalante it walks hands-free, without crutches, using AI-driven dynamic balance. The FDA cleared Eve in August 2026 for eligible adults with spinal cord injuries at any level, provided the user can operate the device's remote control, following a three-site clinical trial that met its functional and usability endpoints. Wandercraft set a US commercial launch for 17 September 2026.
How much does Wandercraft Eve cost?
Wandercraft Eve's price is not publicly disclosed. DEPLOY has no verified price on record for Wandercraft Eve from Wandercraft. Physical-AI systems like this are often sold through enterprise contracts or operated as a service rather than at a public list price; check the manufacturer for the latest.
Is Wandercraft Eve actually deployed in the real world?
Wandercraft Eve is recorded at the commercial stage, but DEPLOY has no deployment verified at a named site yet; vendor deployment claims are not independently confirmed here. Manufacturer capability claims should be read as claims pending independent verification.
Who makes Wandercraft Eve?
Wandercraft Eve is made by Wandercraft, based in Paris, France, founded in 2012.
Can you buy Wandercraft Eve?
Wandercraft Eve is in commercial deployment and is sold to operators; contact the manufacturer to buy, and see the pricing section for any recorded price.
What are alternatives to Wandercraft Eve?
On the DEPLOY registry, comparable exoskeleton robots to Wandercraft Eve include Ant-H1 Pro, Cyberdyne HAL, German Bionic Cray X, HANK.
How does Wandercraft Eve compare to Ant-H1 Pro?
Wandercraft Eve and Ant-H1 Pro (Kenqing Technology · 5 deployments) are both exoskeleton robots on the DEPLOY registry. Wandercraft Eve has 0 verified deployments on record. Compare both records for specs, safety, deployments, and verified-vs-claimed autonomy.
What is Wandercraft Eve's maturity stage?
Wandercraft Eve is at the commercial stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Commercial stage means production-grade deployments are operating at named customer sites.
Where is Wandercraft Eve deployed?
No verified deployments of Wandercraft Eve are currently on the DEPLOY registry. DEPLOY records deployments only when verified at a named site with a primary source; absence may reflect pre-deployment, research, or manufacturer-internal use.
Is Wandercraft Eve safe?
Wandercraft Eve has no incidents on record in the DEPLOY registry. This does not constitute a safety guarantee; it reflects the incidents DEPLOY has tracked and verified to date.
Methodology: Verified · 3 sources (no primary) · last reviewed 2026-09-15

Verification posture

Verified

Low confidence

Review state

Stable

Last reviewed 2026-09-15

Maturity + lifecycle

Maturity stage: commercial

Lifecycle: active

Architectural position

Cohort: exoskeleton

Sources by quality tier

3
unclassified
Unclassified source

The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.

Methodology surface for Wandercraft Eve.